Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 28, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details a specific transaction on April 26, 2006, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust, transferred 6,950 Ordinary Shares. This transfer was executed on behalf of participants in the SmithKline Beecham Employee Share Option Plan 1991.
Outlook, Risks, and Management Commentary
The filing notes that the GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. It clarifies that three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—hold an interest in the shares held within the GSK Trust in the same capacity as other employees. No forward-looking guidance, risk factors, or unusual items are discussed in this text.
Investor Verification Points
- Verify the total number of shares transferred (6,950) and the specific date of the transaction (April 26, 2006).
- Confirm the involvement of the SmithKline Beecham Employee Share Option Plan 1991 in this transfer.
- Note the specific directors identified as having an interest in the trust shares: Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop.
- Understand that this filing does not contain financial results and should not be used for performance analysis.